Probenecid Repurposing for Coronavirus Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapeutics and vaccines are insufficient to effectively manage the rapid spread and severe symptoms of SARS-CoV-2, particularly in older individuals or those with underlying conditions, necessitating the development of new treatments to reduce viral replication and alleviate associated symptoms.
Innovation Solution
Administration of probenecid, its metabolites, or analogs, or pharmaceutically acceptable salts, either systemically or locally, in various dosage forms and routes, including oral, parenteral, topical, or mucosal administration, to reduce viral replication and alleviate symptoms such as fever, congestion, cough, and shortness of breath.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral therapeutics and vaccines are used, then some level of protection is provided, but they are insufficient to effectively manage the rapid spread and severe symptoms of SARS-CoV-2
Solution Approach 1:
The patent utilizes probenecid, a known pharmaceutical agent with established safety profile, and repurposes it for coronavirus treatment by changing its application context and dosage parameters. This approach leverages existing drug properties while modifying treatment parameters to address the specific needs of SARS-CoV-2 management
Solution Approach 2:
Probenecid acts as an intermediary substance that interferes with viral replication processes without directly targeting the virus. The drug modulates the biological environment to inhibit viral propagation, providing a indirect but effective mechanism of action against SARS-CoV-2
2Quantity of substance
If new antiviral treatments are developed to reduce viral replication, then viral load decreases, but treatment complexity and development time increase
Solution Approach 1:
The patent performs preliminary action by identifying and evaluating probenecid's potential against coronaviruses before the SARS-CoV-2 pandemic fully developed. Preclinical studies and mechanistic understanding were established in advance, allowing for rapid translation to clinical use when the pandemic emerged
Solution Approach 2:
The patent employs a repurposed drug with existing manufacturing infrastructure and regulatory approval, avoiding the need for expensive, time-consuming development of entirely new antivirals. This approach uses readily available pharmaceutical resources to address the pandemic quickly
Data Source
AI summary
Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or anaolg thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.